AngioDynamics, Inc. reported a revenue of $292.5 million for the fiscal year ending May 31, 2025, reflecting a decrease of 3.8% compared to the previous year’s revenue of $303.9 million. The decline in revenue was primarily attributed to the divestiture of several product lines, including the PICCs, Midline, dialysis, and BioSentry businesses, which collectively impacted sales by approximately $33.4 million. Despite the overall revenue decline, the company’s Med Tech segment experienced a growth of 19.0%, driven by increased sales of the Auryon system and the thrombus management platform, while the Med Device segment saw a significant decrease of 16.0%.
The company reported a net loss of $34.0 million, or $0.83 per diluted share, a notable improvement from a net loss of $184.3 million, or $4.59 per diluted share, in the prior fiscal year. This reduction in net loss was supported by an increase in gross margin, which rose by 300 basis points to 53.9%. The gross margin improvement was influenced by favorable sales volume and product mix, despite challenges posed by inflationary costs and the divestiture of lower-margin product lines.
Strategically, AngioDynamics has focused on enhancing its Med Tech segment, which is dedicated to improving treatment options for cardiovascular disease and cancer. The company has made significant investments in research and development, resulting in several key product advancements, including FDA 510(k) clearance for the NanoKnife Prostate Tissue Ablation and CE mark approval for the Auryon system. Additionally, the company has initiated clinical trials to support the efficacy of its products, such as the RECOVER-AV trial for the AlphaVac system.
Operationally, AngioDynamics has undergone restructuring to optimize its manufacturing capabilities, including a shift to a partially outsourced model. This restructuring is expected to generate annual cost savings of $15 million starting in fiscal year 2027. As of May 31, 2025, the company had approximately 675 full-time employees, and it continues to focus on maintaining a skilled workforce to support its growth initiatives. The company’s cash and cash equivalents totaled $55.9 million, down from $76.1 million the previous year, but it maintains a strong liquidity position to support ongoing operations and strategic investments.
Looking ahead, AngioDynamics anticipates continued challenges from market dynamics, including inflation and supply chain disruptions. However, the company remains committed to expanding its product offerings and geographic reach, with a focus on driving growth in its Med Tech segment. The management is optimistic about the potential for new product introductions and the ongoing development of existing technologies to enhance patient outcomes and improve financial performance.
About ANGIODYNAMICS INC
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.